Gilead nears deal to buy Immunomedics for more than $20 billion: Report

Discussions between Gilead Sciences and Immunomedics were initially centered around a partnership before shifting to a full-fledged takeover negotiation.

Pfizer signs deal to manufacture and supply Gilead's remdesivir for COVID-19 treatment

The US drugmaker would provide contract manufacturing services at its facility in Kansas to produce the drug.

Gilead's COVID-19 antiviral remdesivir gets conditional EU clearance

The decision comes just days after the company allocated nearly all of its supply of the antiviral to the United States over the next three months, stirring concerns about availability elsewhere.

Coronavirus pandemic | Gilead Sciences will not launch remdesivir in India in July: Report

Hetero Labs and Cipla are the only Indian companies to have received the regulatory approval to market the experimental COVID-19 drug.

Coronavirus drug | Dr Reddy's inks pact with Gilead Sciences to manufacture remdesivir

As per the non-exclusive licensing agreement, Gilead will grant Dr Reddy's Laboratories the right to register and manufacture its investigational Coronavirus drug remdesivir in 127 countries.

AstraZeneca contacted Gilead over potential megamerger: Report

Such a deal would unite two of the drugmakers at the forefront of the industry's efforts to fight the new coronavirus and could be politically sensitive as governments seek control over potential vaccines or treatments.

COVID-19 treatment | Gilead says Indian licensees free to price Remdesivir: Report

Gilead Sciences' experimental drug Remdesivir has been found to aid in the recovery of COVID-19 patients.

US pharma giant seeks marketing authorisation from India for potential COVID-19 treatment drug

Gilead Sciences, who is the patent holder of the drug, has the complete data about the pre-clinical and clinical studies for remdesivir, sources said.

Cipla: Respiratory pipeline adds oxygen, accumulate

Health groups ask India to rescind Gilead's patents for COVID-19 drug remdesivir

But health access groups say the pacts mean cheaper forms of the drug may not become available in nations seen as non-profitable to the five drugmakers.

Iran-linked hackers recently targeted coronavirus drugmaker Gilead

In one case, a fake email login page designed to steal passwords was sent in April to a top Gilead executive involved in legal and corporate affairs, according to an archived version on a website used to scan for malicious web addresses.

Japan approves Gilead Sciences' remdesivir as COVID-19 drug

Japan reached the decision just three days after the US drugmaker filed for fast-track approval for the treatment.

Exclusive: Gilead says open to collaborate with govts, drug firms to make Remdesivir globally available

There is a possibility of Indian companies becoming part of the consortium, in the past Gilead used voluntary licenses to rope in Indian cos to manufacture and launch HIV and hepatitis-C medications in low-middle-income countries (LMICs).

US FDA moving with 'lightning speed' on Gilead's COVID-19 drug: Report

"We're working with the company to emphasize the necessity of speed while at the same time to understand the data," FDA Commissioner Stephen Hahn said.

US stock index futures jump after Gilead's COVID-19 drug meets main goal

Data from the Commerce Department said gross domestic product fell at a 4.8 percent annualized rate in the January-to-March period, while economists in a Reuters poll were expecting a contraction of 4 percent.

Gilead puts emergency access to experimental coronavirus drug on hold amid surging demand

Remdesivir has been touted by many - including President Donald Trump - as one of the more promising potential treatments for the virus.

Editor's Take | Drug companies in race to find vaccine and eliminate COVID-19

Moneycontrol's Shraddha Sharma talks to Prince Thomas to find out what drug companies are doing to find a cure for coronavirus.

Gilead warns against Hep C drugs from buyers clubs, says patients may be at risk

Gilead warned that those (generic versions) medicines have not been approved for use in the countries into which they are imported.

Natco gets DCGI nod to launch hepatitis C drug in India

“The company has received approval for the generic version of ledipasvir + sofosbuvir combination from Drugs Controller General (India)”, Natco Pharma said in a BSE filing today.

Gilead Sciences to set up manufacturing unit in Hyderabad

According to a press release issued by the Telangana government, Senior Director, South East Asia and Pacific, Aaron Brinkworth and Director, Government Affairs - Asia, Claudio Lilienfeld of Gilead Sciences met Chief Minister K Chandrasekhar Rao in camp office along with their team.

Battle coming for blockbuster cholesterol drugs

The injectable drugs, known as PCSK9 inhibitors, could cost an estimated USD 7,000 to USD 12,000 per year for each person using the drug.

Mylan launches Sovaldi tablets in India

In February this year, Gilead appointed Mylan as its exclusive distributor of Sovaldi in India. Mylan president Rajiv Malik said they have a history of partnering with Gilead to tackle key public health issues in India and around the world, beginning with expanding access to high quality and affordable HIV/AIDS antiretrovirals.

Cipla to launch generic Hepatitis C drug 'Hepcvir' in India

The availability of product in other markets is subject to approvals from the regulatory authorities in respective countries, Cipla said.

Dr Reddy's up 2% on pact with Hetero for Hepatitis drug

Shares of Dr Reddy's Laboratories gained 1.7 percent intraday Tuesday on agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences' Hepatitis C drug under the brand 'Resof' in India.

Zydus Cadila launches Gilead's Hepatitis C drug in India

Zydus Cadila had recently signed a non-exclusive licensing agreement with Gilead Sciences to manufacture Sofosbuvir and the fixed dose combination of Ledipasvir/ Sofosbuvir for distribution in 91 developing countries including India.